• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝门部胆管癌临床美国癌症联合委员会 T 分期的优越性。

Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma.

机构信息

Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan.

出版信息

J Hepatobiliary Pancreat Sci. 2022 Jul;29(7):768-777. doi: 10.1002/jhbp.1066. Epub 2021 Nov 9.

DOI:10.1002/jhbp.1066
PMID:34717042
Abstract

BACKGROUND

Clinical tumor staging is essential information for making a therapeutic decision in cancer. This study aimed to identify the optimal tumor classification system for predicting resectability and survival probability in perihilar cholangiocarcinoma.

METHODS

Patients who were treated for perihilar cholangiocarcinoma between 2009 and 2018 were enrolled. Local tumor extension was staged radiologically according to a diameter-based classification system in addition to the AJCC, Blumgart, and Bismuth systems. Survival and resectability were compared between T subgroups, and the discriminability of the four systems was assessed with Harrell's concordance index (C-index).

RESULTS

Among 702 study patients, 559 (80.0%) underwent laparotomy, 489 (70.0%) of whom underwent resection. The resectability significantly decreased for more advanced tumors in all systems (P < .001); the AJCC system had the greatest discriminability for resectability (area under the curve 0.721). Overall survival at 5 years was 69.9% for AJCC cT1, 45.8% for cT2, 31.8% for cT3, and 15.3% for cT4 tumors (cT1 vs cT2; P = .002, cT2 vs cT3; P = .008 and cT3 vs cT4; P < .001). The AJCC system had the largest C-index of 0.627.

CONCLUSIONS

The AJCC T system was the optimal classification system for predicting resectability and survival in perihilar cholangiocarcinoma.

摘要

背景

临床肿瘤分期是制定癌症治疗决策的重要信息。本研究旨在确定最佳的肿瘤分类系统,以预测肝门部胆管癌的可切除性和生存概率。

方法

纳入 2009 年至 2018 年间接受肝门部胆管癌治疗的患者。根据基于直径的分类系统对局部肿瘤进行影像学分期,除了 AJCC、Blumgart 和 Bismuth 系统外。比较 T 亚组之间的生存和可切除性,并使用 Harrell 一致性指数(C 指数)评估四个系统的区分能力。

结果

在 702 例研究患者中,559 例(80.0%)接受了剖腹手术,其中 489 例(70.0%)接受了切除术。在所有系统中,进展期肿瘤的可切除性显著降低(P<0.001);AJCC 系统对可切除性的区分能力最强(曲线下面积 0.721)。AJCC cT1 组的 5 年总生存率为 69.9%,cT2 组为 45.8%,cT3 组为 31.8%,cT4 组为 15.3%(cT1 与 cT2;P=0.002,cT2 与 cT3;P=0.008,cT3 与 cT4;P<0.001)。AJCC 系统的 C 指数最大,为 0.627。

结论

AJCC T 系统是预测肝门部胆管癌可切除性和生存的最佳分类系统。

相似文献

1
Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma.肝门部胆管癌临床美国癌症联合委员会 T 分期的优越性。
J Hepatobiliary Pancreat Sci. 2022 Jul;29(7):768-777. doi: 10.1002/jhbp.1066. Epub 2021 Nov 9.
2
Predictive performance of Blumgart T staging for perihilar cholangiocarcinoma in a Japanese center.日本中心对胆门周围型胆管癌的 Blumgart T 分期的预测性能。
J Hepatobiliary Pancreat Sci. 2020 Mar;27(3):132-140. doi: 10.1002/jhbp.694. Epub 2019 Nov 28.
3
Proposal for a new classification for perihilar cholangiocarcinoma based on tumour depth.基于肿瘤深度的肝门周围胆管癌新分类建议。
Br J Surg. 2019 Mar;106(4):427-435. doi: 10.1002/bjs.11063. Epub 2019 Jan 24.
4
Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma.淋巴细胞与单核细胞比值预测可切除性和毕氏Ⅳ型肝门胆管癌早期复发。
J Gastrointest Surg. 2020 Feb;24(2):330-340. doi: 10.1007/s11605-018-04086-9. Epub 2019 Jan 22.
5
Comparison of the 7th and 8th editions of the American Joint Committee on Cancer Staging Systems for perihilar cholangiocarcinoma.比较第 7 版和第 8 版美国癌症联合委员会肝胆管癌分期系统。
Surgery. 2018 Aug;164(2):244-250. doi: 10.1016/j.surg.2018.03.012. Epub 2018 May 24.
6
[Intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma -differentiation in terms of imaging diagnoses and surgical procedures].[肝内胆管癌和肝门部胆管癌——在影像学诊断和手术操作方面的鉴别]
Nihon Shokakibyo Gakkai Zasshi. 2016 Sep;113(9):1550-6. doi: 10.11405/nisshoshi.113.1550.
7
Evaluation of the New American Joint Committee on Cancer Staging Manual 8th Edition for Perihilar Cholangiocarcinoma.新版美国癌症联合委员会癌症分期手册第 8 版评估肝门周围胆管癌。
J Gastrointest Surg. 2020 Jul;24(7):1612-1618. doi: 10.1007/s11605-019-04127-x. Epub 2019 Feb 12.
8
Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme.肝门部胆管癌:检查的淋巴结数量及最佳淋巴结预后方案
J Am Coll Surg. 2016 May;222(5):750-759.e2. doi: 10.1016/j.jamcollsurg.2016.02.012. Epub 2016 Feb 26.
9
Prediction of prognosis and resectability using MR imaging, clinical, and histopathological findings in patients with perihilar cholangiocarcinoma.使用 MRI 成像、临床和组织病理学检查结果预测肝门周围胆管癌患者的预后和可切除性。
Abdom Radiol (NY). 2021 Sep;46(9):4159-4169. doi: 10.1007/s00261-021-03101-z. Epub 2021 Apr 30.
10
[Benign hilar bile duct stricture resected as perihilar cholangiocarcinoma].[按照肝门部胆管癌手术方式切除的良性肝门部胆管狭窄]
Nihon Shokakibyo Gakkai Zasshi. 2020;117(8):679-688. doi: 10.11405/nisshoshi.117.679.

引用本文的文献

1
Perihilar cholangiocarcinoma: a surgeon's perspective.肝门部胆管癌:外科医生的视角
ILIVER. 2022 Apr 5;1(1):12-24. doi: 10.1016/j.iliver.2022.03.004. eCollection 2022 Mar.
2
Endoscopic treatment of unresectable perihilar cholangiocarcinoma: beyond biliary drainage.不可切除性肝门部胆管癌的内镜治疗:超越胆道引流
Therap Adv Gastroenterol. 2025 Apr 14;18:17562848251328595. doi: 10.1177/17562848251328595. eCollection 2025.
3
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.
超低位剂量二元溶瘤/辅助依赖性腺病毒在临床前和临床研究中促进抗肿瘤活性。
Sci Adv. 2023 Mar 29;9(13):eade6790. doi: 10.1126/sciadv.ade6790.